Immunotherapy: new options in breast cancer treatment

References

• Morse MA. Technology evaluation: Theratope, Biomira, Inc. Curr. Opin. Mot Then 2(4), 453–458 (2000).
   Google Scholar
• Miles DW, Towlson KE, Graham R et aZ A randomised Phase II study of sialyl-Tn and detox-B adjuvant with or without cyclophospharnide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 74,1292 (1996).
   PubMed Web of Science ®Google Scholar
• Holmberg LA, Sandmaier BM. Theratope vaccine (STn-KLH). E. Opin. Biol. Then 1(5), 881–891 (2001).
   Google Scholar
• Chazin VR, Kaledo M, Miller AD et aZ Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7(9), 1859–1866 (1992).
   Google Scholar
• Pegram MD, Baly D, Wirth C. Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of humanized antiHER-2 antibody. Proc. Am. Assoc. Cancer Res. 38,602 (1997).
   Google Scholar
• Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Toikkanen S, Helin H, Isola J et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up." Clin. Oncol. 10, 1044 1048 (1992).
   Google Scholar
• Buehler HJ, Kuter I, Richardson PG et al. Effective Her-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH. Proc. Am. Soc. Clin. Onca 19,76a (2000) (Abstract 294).
   Google Scholar
• Mass RD, Sanders C, Charlene K et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials. Proc. Am. Soc. Clin. Oncol. 19,75a (1999) (Abstract 291).
   Google Scholar
• Seidman AD, Fomire M, Esteva F et aZ Final report: weekly herceptin and taxol for metastatic breast cancer (MBC): analysis of efficacy in Her-2/neu immunophenotype (IHC) and gene amplification (FISH). Proc. Am. Soc. Clin. Oncol. 19,83a (2000) (Abstract 319).
   Google Scholar
• Cobleigh A, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized antiHER-2 monoclonal antibody in women who have HER-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Onca 17(9), 2639–2648 (1999).
   Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. First-line herceptin monotherapy in metastatic breast cancer. Oncology 61\(Suppl. 2), 37–42 (2001).
   Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Superior outcomes with herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients. Proc. Am. Soc. Clin. Oncol. 24,86 (2001).
   Google Scholar
• Esteva FJ, Seidman AD, Fomier M et aZ Analysis of response to weekly lh taxol plus herceptin by immunophenotypic analysis in Her-2/neu overexpression (Her-2/neu +) and non-expressing (Her-2/neu-) metastatic breast cancer. Breast Cancer Res. Treat. 57,29 (1999) (Abstract 17).
   Google Scholar
• ••The biggest clinical trial conducted withtrastuzumab so far. It led to the US approval of trastuzumab for the treatment of advanced HER-2 overexpression breast cancer in 1998.
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N EngZ I Med. 344(11) 783–792 (2001).
   Google Scholar
• Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer. Clin. Oncol. 19(10), 2722–2730 (2001).
   Google Scholar
• Konecny G, Untch M, Crohns C et al. c-erbB-2: Uberexpression und herceptin® in der therapie des marnmakarzinoms. In: Diagnostik und Therapie des Mammakarzinonzs.W Zuckschwer, Munchen, Germany (2000).
   Google Scholar
• Borg A, Baldetorp B, Fernö M et al. ErbB-2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81,137–144 (1994).
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Green S, Albain KS et at Initial report of the SWOG Biological Correlative Study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen (T) alone. Proc. Am. Soc. Clin. Oncol. 17, 97a (1998).
   Google Scholar
• Mass R, Cobleigh M, Vogel C et al. Estrogen receptor status in the herceptin (trastuzumab) clinical trials: incidence and relation to clinical benefit. Proc. Am. Soc. Clin. Oncol. 24,522 (2001).
   Google Scholar
• Lipton A, Mouridsen H, Ali S et al. Serum Her-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. Proc. Am. Soc. Clin. Oncol. 24 (2001).
   Google Scholar
• •Study assessing correlations of HER-2 overexpression and hormone receptor expression with spectacular results
   Google Scholar
• Konecny G, Pauletti G, Pegrarn M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer." Natl Cancer Inst. 95,142-153 (2003).
   Google Scholar
• Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophospharnide for HER2 overexpressing Stage II or III breast cancer: a pilot study." Clin. Oncol. 21(1), 46–53 (2003).
   Google Scholar